NCT01522664 (Clinical Trial/ DEDN6526A/ RG7636/ RG-7636)

Study Title
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma (NCT01522664)

Trial Description
This multicenter, open-label study will assess the safety and pharmacokinetics of DEDN6526A (also known as RG7636 or RG-7636) in patients with metastatic or unresectable melanoma. Cohorts of patients will receive escalating doses of DEDN6526A by intravenous infusion on Day 1 of each 21-day cycle. In the absence of disease progression or unacceptable toxicity, patients may continue to receive DEDN6552A for up to 17 cycles (1 year). This trial is sponsored by Genentech/Roche.

Study Data

  • Condition: Melanoma
  • Interventions:
    • Drugs used in this trial
      • DEDN6526 (ARG7636; RG-7636)
  • Enrollment: 53
  • Start: March 2012
  • Estimated Completion: April 2015
  • Last verified: April 2015

Study Schematic


Screen Shot 2016-07-06 at 4.31.44 PM

Click here to Return to Drug map

Last Editorial review: July 7, 2016
Information based on (NIH/NCI) and other sources.